Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4)

被引:22
作者
Mumaw, Michele M. [1 ]
de la Fuente, Maria [1 ]
Arachiche, Amal [1 ]
Wahl, James K., III [2 ]
Nieman, Marvin T. [1 ]
机构
[1] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA
[2] Univ Nebraska Med Ctr, Coll Dent, Dept Oral Biol, Lincoln, NE USA
基金
美国国家卫生研究院;
关键词
Protease activated receptor 4; Monoclonal antibody; G-protein coupled receptor; Thrombin receptor; Platelets; HUMAN PLATELET-AGGREGATION; THROMBIN RECEPTOR; ALPHA-THROMBIN; SIGNALING AXIS; CLEAVAGE; MECHANISM; SITE; RACE; INFLAMMATION; STIMULATION;
D O I
10.1016/j.thromres.2015.03.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Protease activated receptor 4 (PAR4) is a G protein coupled receptor (GPCR) which is activated by proteolytic cleavage of its N-terminal exodomain. This generates a tethered ligand that activates the receptor and triggers downstream signaling events. With the current focus in the development of anti-platelet therapies shifted towards PARs, new reagents are needed for expanding the field's knowledge on PAR4. Currently, there are no PAR4 reagents which are able to detect activation of the receptor. Methods: Monoclonal PAR4 antibodies were purified from hybridomas producing antibody that were generated by fusing splenocytes with NS-1 cells. Immunoblotting, immunofluorescence, and flow cytometry were utilized to detect the epitope for each antibody and to evaluate the interaction of the antibodies with cells. Results: Here, we report the successful generation of three monoclonal antibodies to the N-terminal extracellular domain of PAR4: 14H6, 5 F10, and 2D6. We mapped the epitope on PAR4 of 14H6, 5 F10, and 2D6 antibodies to residues (48-53), (41-47), and (73-78), respectively. Two of the antibodies (14H6 and 5 F10) interacted close to the thrombin cleavage and were sensitive to alpha-thrombin cleavage of PAR4. In addition, 5 F10 was able to partially inhibit the cleavage of PAR4 expressed in HEK293 cells by alpha-thrombin. Conclusions: These new antibodies provide a means to monitor endogenous PAR4 expression and activation by proteases on cells. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1165 / 1171
页数:7
相关论文
共 50 条
[31]   Protease-activated receptor 4 deficiency offers cardioprotection after acute ischemia reperfusion injury [J].
Kolpakov, Mikhail A. ;
Rafiq, Khadija ;
Guo, Xinji ;
Hooshdaran, Bahman ;
Wang, Tao ;
Vlasenko, Liudmila ;
Bashkirova, Yulia V. ;
Zhang, Xiaoxiao ;
Chen, Xiongwen ;
Iftikhar, Sahar ;
Libonati, Joseph R. ;
Kunapuli, Satya P. ;
Sabri, Abdelkarim .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2016, 90 :21-29
[32]   Evaluation of antibodies directed against human protease-activated receptor-2 [J].
Adams, Mark N. ;
Pagel, Charles N. ;
Mackie, Eleanor J. ;
Hooper, John D. .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2012, 385 (09) :861-873
[33]   Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine [J].
Kopruszinski, Caroline M. ;
Thornton, Peter ;
Arnold, Joanne ;
Newton, Philip ;
Lowne, David ;
Navratilova, Edita ;
Swiokla, Juliana ;
Dodick, David W. ;
Dobson, Claire ;
Gurrell, Ian ;
Chessell, Iain Patrick ;
Porreca, Frank .
CEPHALALGIA, 2020, 40 (14) :1535-1550
[34]   Acetaminophen Overdose Reveals PAR4 as a Low-Expressing but Potent Receptor on the Hepatic Endothelium in Mice [J].
Rajala, Rahul ;
Cleuren, Audrey C. A. ;
Griffin, Courtney T. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2025, 45 (01) :53-71
[35]   Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions [J].
Rigg, Rachel A. ;
Healy, Laura D. ;
Chu, Tiffany T. ;
Ngo, Anh T. P. ;
Mitrugno, Annachiara ;
Zilberman-Rudenko, Jevgenia ;
Aslan, Joseph E. ;
Hinds, Monica T. ;
Vecchiarelli, Lisa Dirling ;
Morgan, Terry K. ;
Gruber, Andras ;
Temple, Kayla J. ;
Lindsley, Craig W. ;
Duvernay, Matthew T. ;
Hamm, Heidi E. ;
McCarty, Owen J. T. .
PLATELETS, 2019, 30 (01) :126-135
[36]   Screening of phytochemicals against protease activated receptor 1 (PAR1), a promising target for cancer [J].
Kakarala, Kavita Kumari ;
Jamil, Kaiser .
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2015, 35 (01) :26-45
[37]   Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354 [J].
Wen, Wandong ;
Young, Summer E. ;
Duvernay, Matthew T. ;
Schulte, Michael L. ;
Nance, Kellie D. ;
Melancon, Bruce J. ;
Engers, Julie ;
Locuson, Charles W., II ;
Wood, Michael R. ;
Daniels, J. Scott ;
Wu, Wenjun ;
Lindsley, Craig W. ;
Hamm, Heidi E. ;
Stauffer, Shaun R. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (19) :4708-4713
[38]   Characterizing the interaction modes of PAR4 receptor with agonist and antagonist by molecular simulation approach [J].
Lu, Nan ;
Meng, Fancui ;
Yuan, Jing ;
Liu, Lei ;
Wang, Yanshi ;
Li, Lingjun ;
Zhao, Tong ;
Xu, Weiren ;
Tang, Lida ;
Xu, Youjun .
JOURNAL OF THEORETICAL & COMPUTATIONAL CHEMISTRY, 2019, 18 (02)
[39]   The G protein-coupled protease receptor PAR (protease-activated receptor) as a novel target for drug development [J].
Kawabata, A .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2001, 121 (01) :1-7
[40]   Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart [J].
Fender, Anke C. ;
Kleeschulte, Sonja ;
Stolte, Svenja ;
Leineweber, Katja ;
Kamler, Markus ;
Bode, Johannes ;
Li, Na ;
Dobrev, Dobromir .
BASIC RESEARCH IN CARDIOLOGY, 2020, 115 (02)